Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference

THOUSAND OAKS, Calif., May 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 38th Annual  Healthcare Conference on Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, Boston, beginning at 9:20 a.m. Eastern Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Eric Hyllengren, 805-447-79898 (investors)

SOURCE Amgen

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.